PROVECTUS BIOPHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $20.55M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2016 Ended Sep 30, 2016 | Nov 10, 2016 | After market close | – | – | – |
| Q2 FY2016 Ended Jun 30, 2016 | Aug 9, 2016 | After market close | – | – | – |
| Q3 FY2015 Ended Sep 30, 2015 | Nov 5, 2015 | Before market open | – | – | – |
| Q2 FY2015 Ended Jun 30, 2015 | Aug 6, 2015 | Before market open | – | – | – |
| Q1 FY2015 Ended Mar 31, 2015 | May 7, 2015 | Before market open | – | – | – |
| Q4 FY2014 Ended Dec 31, 2014 | Mar 12, 2015 | Before market open | – | – | – |
Press releases
Announcements Provectus Biopharmaceuticals filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville,
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Introduces Revolutionary Therapy for Severe Eye Infections
Other events · EX-99.1 to Form 8-K
Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharmaceuticals Announces First Quarter 2024 Conference Call
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharmaceuticals Releases 2023 Stockholder Letter
Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharmaceuticals Seeks Stockholder Approval at 2022 Annual Meeting for Authority to Undertake Reverse Split of Outstanding Equities
Other events · EX-99.1 to Form 8-K